Chondroitin-AKOS - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Affects the exchange processes in the hyaline and fibrous cartilage, reduces degenerative changes in the cartilaginous tissue of the joints, stimulates the biosynthesis of glucosaminoglycans.Slows the resorption of bone tissue and reduces calcium loss, accelerates the recovery of bone tissue. In the treatment with the drug Chondroitin-AKOS, soreness decreases and mobility of the affected joints improves. The therapeutic effect persists for a long time after the end of the course of treatment.

Pharmacokinetics:More than 7 0% of chondroitin sulfate is absorbed in the digestive tract. Bioavailability of the drug is 13%. With a single admission of the medial therapeutic dose, the maximum concentration in the plasma is noted after 3-4 hours, in the synovial fluid, after 4-5 hours. Absorbed in the gastrointestinal tract, the drug accumulates in the synovial fluid. It is excreted by the kidneys.

Indications:Degenerative diseases of the joints and spine: osteoarthritis, osteochondrosis of the spine.

Contraindications:

- Hypersensitivity to the components of the drug;

- Children under 15 years of age (due to lack of accurate data).

Carefully:Bleeding and a tendency to bleeding, thrombophlebitis.

Pregnancy and lactation:The drug is not recommended to be prescribed during pregnancy and lactation due to the lack of sufficient clinical data.

Dosing and Administration:Inside, during or after a meal, drinking at least 1/2 cup of water. Adults and adolescents with 15 years of age appoint 1 g per day - 2 capsules 2 times a day. The recommended duration of the initial course of treatment is 6 months, the period of the drug after its withdrawal is 3-5 months depending on the location and stage of the disease, the duration of repeated courses of treatment is established by the doctor.

Side effects:Rarely: allergic reactions (urticaria, erythema, pruritus), nausea, vomiting.

Overdose:In rare cases, symptoms of an overdose on the part of the gastrointestinal tract are possible: nausea, vomiting, diarrhea; with prolonged intake of excessively high doses (over 3 g / day), hemorrhagic eruptions are possible. Treatment is symptomatic.

Interaction:With the simultaneous use of Chondroitin-AKOS with other drugs, the effect of indirect anticoagulants, antiplatelet agents, fibrinolytic agents may be increased.

Special instructions:Caution should be given to patients with bleeding, as well as patients with a tendency to bleeding.

Form release / dosage:Capsules 250 mg.

Packaging:For 10 pieces in a planar cell pack. 2, 5, 6 contour squares with instructions for use are placed in a pack of cardboard.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° FROM.

Keep out of the reach of children.

Shelf life:3 years. Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:P N000545 / 02

Date of registration:29.08.2008

The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia

Manufacturer: & nbsp

SYNTHESIS, OJSC Russia

Information update date: & nbsp06.10.2015

Illustrated instructions

Instructions

Chondroitin-Akos (Chondroitin-AKOS)